Medpace (NASDAQ:MEDP) Shares Acquired Rep. David Taylor

Posted by Geri Gentry on May 30th, 2026

Representative David Taylor (Republican-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on May 28th, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on May 15th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 5/15/2026.
Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 5/15/2026.
Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
Purchased $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 5/15/2026.
Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 5/15/2026.
Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 4/27/2026.
Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 4/27/2026.
Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 4/27/2026.
Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 4/27/2026.

Medpace Price Performance

Medpace stock opened at $447.11 on Friday. The stock has a market cap of $12.77 billion, a P/E ratio of 28.10, a PEG ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a 1 year low of $291.28 and a 1 year high of $628.92. The firm’s 50 day moving average price is $457.47 and its 200-day moving average price is $513.97.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.50% of the stock is owned by insiders.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MEDP shares. Leerink Partners reduced their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Robert W. Baird reduced their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Mizuho set a $582.00 price objective on shares of Medpace in a research report on Wednesday, February 11th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Barclays cut their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $467.08.

Get Our Latest Report on MEDP

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Argent Capital Management LLC grew its holdings in shares of Medpace by 0.3% in the first quarter. Argent Capital Management LLC now owns 76,590 shares of the company’s stock valued at $36,778,000 after purchasing an additional 250 shares in the last quarter. Turtle Creek Asset Management Inc. grew its holdings in shares of Medpace by 4,741.8% in the first quarter. Turtle Creek Asset Management Inc. now owns 135,570 shares of the company’s stock valued at $65,099,000 after purchasing an additional 132,770 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Medpace by 29.9% in the first quarter. NewEdge Advisors LLC now owns 2,473 shares of the company’s stock valued at $1,188,000 after purchasing an additional 569 shares in the last quarter. Bank of America Corp DE boosted its stake in Medpace by 0.7% during the first quarter. Bank of America Corp DE now owns 212,183 shares of the company’s stock worth $101,888,000 after buying an additional 1,487 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Medpace by 21.0% during the first quarter. Janus Henderson Group PLC now owns 124,954 shares of the company’s stock worth $60,026,000 after buying an additional 21,709 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.